Synopsys (SNPS) PT Raised to $85 at DA Davidson Following 2Q

Synopsys (SNPS) PT Raised to $86 at Pacific Crest

Pacific Crest raised its price target on Synopsys (NASDAQ: SNPS) to $86.00 (from $78.00) while maintaining a Overweight rating following another strong beat and raise quarter.

Synopsys (SNPS): Beat, Raise and Guidance Still Conservative - Needham

Needham & Company analyst, Richard Valera, reiterated his Buy rating on shares of Synopsys (NASDAQ: SNPS) and raised his price target to $77 after the company reported strong 2Q results and upside 3Q guidance. The company benefited from stronger than expected hardware sales and timing... More

After-Hours Stock Movers 05/17: (GLYC) (P) (INCY) Higher; (ASNA) (SMRT) (CSCO) Lower (more...)

Today's After-Hours Movers:

GlycoMimetics, Inc. (NASDAQ: GLYC) 37.4% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for treatment of adult relapsed/refractory acute myeloid leukemia (AML) to the companys drug candidate GMI-1271, an E-selectin antagonist currently being evaluated in the Phase 2 portion of a Phase 1/2 clinical trial in patients with AML. The U.S. Food and Drug Administration (FDA) had previously granted Orphan Drug designation and Fast Track Status for GMI-1271 in AML.

ascena retail group, inc.... More

Synopsys (SNPS) Tops Q2 EPS by 2c, Beats on Revenues; Offers Positive FY17 Guidance

Synopsys (NASDAQ: SNPS) reported Q2 EPS of $0.88, $0.02 better than the analyst estimate of $0.86. Revenue for the quarter came in at $680.1 million versus the consensus estimate of $672.4 million.

GUIDANCE:

Synopsys sees FY2017 EPS of $3.24-$3.29, versus the consensus of $3.25. Synopsys sees FY2017 revenue of $2.65-2.67 billion, versus the... More